Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35

Cancer Research

Volumn 62, Issue 23, 2002, Pages 6928-6937

  Schwartz, Pamela S ^a   Chen, Chong Sheng ^a   Waxman, David J ^a  

^a Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE INHIBITOR; CHEMICAL AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450; ENZYME; PRODRUG; PROTEIN P35;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACULOVIRUS; BOLUS INJECTION; BYSTANDER EFFECT; CELL DEATH; CELL KILLING; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME DEFECT; GENE; GENE THERAPY; NONHUMAN; PERIODICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR CELL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BIOTRANSFORMATION; CASPASES; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; GENE THERAPY; GLIOSARCOMA; GLUTATHIONE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NADPH-FERRIHEMOPROTEIN REDUCTASE; PRODRUGS; RATS; TUMOR CELLS, CULTURED; VIRAL PROTEINS;

EID: 0036894385     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Moore, M. J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet., 20: 194-208. 1991.
2. Roy, P., Yu, L. J., Crespi, C. L., and Waxman, D. J. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab. Dispos., 27: 655-666, 1999.
3. Jounaidi, Y., Hecht, J. E., and Waxman, D. J. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res., 58: 4391-4401, 1998.
4. Wei, M. X., Tamiya, T., Chase, M., Boviatsis, E. J., Chang, T. K. H., Kowall, N. W., Hochberg, F. H., Waxman, D. J., Breakefield, X. O., and Chiocca, E. A. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther., 5: 969-978, 1994.
5. Chen, L., and Waxman, D. J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res., 55: 581-589, 1995.
6. Chen, L., and Waxman, D. J. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr. Pharm. Des., 8: 1405-1416, 2002.
7. Chiocca, E. A., and Waxman, D. J., Cytochrome P450-based gene therapies for cancer. In: Suicide Gene Therapy: Methods and Protocols for Cancer. Totawa, NJ: Humana Press, 2003. in press.
8. Kan, O., Griffiths, L., Baban, D., Iqball, S., Uden, M., Spearman, H., Slingsby, J., Price, T., Esapa, M., Kingsman, S., Kingsman, A., Slade, A., and Naylor, S. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther., 8: 473-482, 2001.
9. Schwartz, P. S., and Waxman, D. J. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol. Pharmacol., 60: 1268-1279, 2001.
10. Nunez, G., Benedict, M. A., Hu, Y., and Inohara, N. Caspases: The proteases of the apoptotic pathway. Oncogene, 17: 3237-3245, 1998.
11. Scaffidi, C., Schmitz, I., Zha, J., Korsmeyer, S. J., Krammer, P. H., and Peter, M. E. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem., 274: 22532-22538, 1999.
12. Green, D. R. Apoptotic pathways: The roads to ruin. Cell, 94: 695-698, 1998.
13. Ashkenazi, A., and Dixit, V. M. Death receptors: Signaling and modulation. Science (Wash. DC), 281: 1305-1308, 1998.
14. Micheau, O., Solary, E., Hammann, A., and Dimanche-Boitrel, M. T. Fas ligand-independent. FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem., 274: 7987-7992, 1999.
15. Sun, X. M., MacFarlane, M., Zhuang, J., Wolf, B. B., Green, D. R., and Cohen, G. M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem., 274: 5053-5060, 1999.
16. Green, D. R., and Reed, J. C. Mitochondria and apoptosis. Science (Wash. DC), 281: 1309-1312, 1998.
17. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91: 479-489, 1997.
18. Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Brenner, C., Larochette, N., Prevost, M. C., Alzari, P. M., and Kroemer, G. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J. Exp. Med., 189: 381-394, 1999.
19. Slee, E. A., Harte, M. T., Kluck, R. M., Wolf, B. B., Casiano, C. A., Newmeyer, D. D., Wang, H. G., Reed, J. C., Nicholson, D. W., Alnemri, E. S., Green, D. R., and Martin, S. J. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol., 144: 281-292, 1999.
20. Rizk, N. P., Chang, M. Y., El Kouri, C., Seth, P., Kaiser, L. R., Albelda, S. M., and Amin, K. M. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer. Cancer Gene Ther., 6: 291-301, 1999.
21. Kagawa, S., Gu, J., Swisher, S. G., Ji, L., Roth, J. A., Lai, D., Stephens, L. C., and Fang, B. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res., 60: 1157-1161, 2000.
22. Kagawa, S., He, C., Gu, J., Koch, P., Rha, S. J., Roth, J. A., Curley, S. A., Stephens, L. C., and Fang, B. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res., 61: 3330-3338, 2001.
23. Komata, T., Kondo, Y., Kanzawa, T., Hirohata, S., Koga, S., Sumiyoshi, H., Srinivasula, S. M., Barna, B. P., Germano, I. M., Takakura, M., Inoue, M., Alnemri, E. S., Shay, J. W., Kyo, S., and Kondo, S. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res., 61: 5796-5802, 2001.
24. Xie, X., Zhao, X., Liu, Y., Zhang, J., Matusik, R. J., Slawin, K. M., and Spencer, D. M. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res., 61: 6795-6804, 2001.
25. Ozols, R. F., Louie, K. G., Plowman, J., Behrens, B. C., Fine, R. L., Dykes, D., and Hamilton, T. C. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem. Pharmacol., 36: 147-153, 1987.
26. Waxman, D. J. Glutathione S-transferases: Role in alkylating agent resistance and possible target for modulation chemotherapy - A review. Cancer Res., 50: 6449-6454, 1990.
27. Chen, G., and Waxman, D. J. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Biochem. Pharmacol., 47: 1079-1087, 1994.
28. Sahovic, E. A., Colvin, M., Hilton, J., and Ogawa, M. Role for aldehyde dehydrogenase in survival of progenitors for murine blast cell colonies after treatment with 4-hydroperoxycyclophosphamide in vitro. Cancer Res., 48: 1223-1226, 1988.
29. Russo, J. E., Hilton, J., and Colvin, O. M. The role of aldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide. Prog. Clin. Biol. Res., 290: 65-79, 1989.
30. Sladek, N. E. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr. Pharm. Des., 5: 607-625, 1999.
31. Deveraux, Q. L., and Reed, J. C. IAP family proteins-suppressors of apoptosis. Genes Dev., 13: 239-252, 1999.
32. Roy, N., Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J., 16: 6914-6925, 1997.
33. Ambrosini, G., Adida, C., and Altieri, D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 3: 917-921, 1997.
34. Yamamoto, T., and Tanigawa, N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med. Electron. Microsc., 34: 207-212, 2001.
35. Clem, R. J., Fechheimer, M., and Miller, L. K. Prevention of apoptosis by a baculovirus gene during infection of insect cells. Science (Wash. DC), 254: 1388-1390, 1991.
36. Jounaidi, Y., and Waxman, D. J. Frequent, moderate dose cyclophosphamide administration improves the efficacy of P450/P450 reductase-based cancer gene therapy. Cancer Res., 61: 4437-4444, 2001.
37. Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA. 90: 8392-8396, 1993.
38. Hecht, J., Jounaidi, Y., and Waxman, D. J. Construction of P450-expressing tumor cell lines using retroviruses. In: W. Walther and U. Stein (eds.), Gene Therapy of Cancer, pp. 85-94, Totowa, NJ: Humana Press, 2000.
39. Talanian, R. V., Quinlan, C., Trautz, S., Hackett, M. C., Mankovich, J. A., Banach, D., Ghayur, T., Brady, K. D., and Wong, W. W. Substrate specificities of caspase family proteases. J. Biol. Chem., 272: 9677-9682, 1997.
40. Thomberry, N. A., Rano, T. A., Peterson, E. P., Rasper, D. M., Timkey, T., Garcia-Calvo, M., Houtzager, V. M., Nordstrom, P. A., Roy, S., Vaillancourt, J. P., Chapman, K. T., and Nicholson, D. W. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem., 272: 17907-17911, 1997.
41. Huang, Z., and Waxman, D. J. High-performance liquid chromatographic-fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anticancer drug ifosfamide, in plasma and in liver microsomal incubations. Anal. Biochem., 273: 117-125, 1999.
42. O'Brien, M. L., and Tew, K. D. Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer. 32A: 967-978, 1996.
43. Gamcsik, M. P., Dolan, M. E., Andersson, B. S., and Murray, D. Mechanisms of resistance to the toxicity of cyclophosphamide. Curr. Pharm. Des., 5: 587-605, 1999.
44. Ayash, L. J., Wright, J. E., Tretyakov, O., Gonin, R., Elias, A., Wheeler, C., Eder, J. P., Rosowsky, A., Antman, K., and Frei, E., 3rd Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumor response. J. Clin. Oncol., 10: 995-1000, 1992.
45. Antman, K., Ayash, L., Elias, A., Wheeler, C., Hunt, M., Eder, J. P., Teicher, B. A., Critchlow, J., Bibbo, J., Schnipper, L. E., and et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J. Clin. Oncol., 10: 102-110, 1992.
46. Sladek, N. E. Metabolism of oxazaphosphorines. Pharmacol. Ther. 37: 301-355, 1988.
47. Juma, F. D., Rogers, H. J., and Trounce, J. R. The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. Br. J. Clin. Pharmacol., 10: 327-335, 1980.
48. Pope, I. M., Poston, G. J., and Kinsella, A. R. The role of the bystander effect in suicide gene therapy. Eur. J. Cancer, 33: 1005-1016, 1997.
49. Springer, C. J., and Niculescu-Duvaz, I. Prodrug-activating systems in suicide gene therapy. J. Clin. Investig., 105: 1161-1167, 2000.
50. Wei, M. X., Tamiya, T., Rhee, R. J., Breakefield, X. O., and Chiocca, E. A. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin. Cancer Res., 1: 1171-1177, 1995.
51. Dorr, R., T., and Van Hoff, D., D. Cancer Chemotherapy Handbook, Ed. 2, pp. 319-328, Norwalk. CT: Appleton and Lange, 1994.
52. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000.
53. Reed, J. C. Bcl-2 family protiens: Relative importance as determinants of chemoresistance in cancer. In: J. A. Hickman and C. Dive (eds.), Apoptosis and Cancer Chemotherapy, 5 Ed., pp. 99-116. Totowa, NJ: Humana Press, 1999.
54. Zornig, M., Hueber, A., Baum, W., and Evan, G. Apoptosis regulators and their role in tumorigenesis. Biochim. Biophys. Acta, 1551: F1-F37, 2001.
55. Deigner, H. P., Haberkorn, U., and Kinscherf, R. Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin. lnvestig. Drugs, 9: 747-764, 2000.
56. Aebischer, P., and Ridet, J. Recombinant proteins for neurodegenerative diseases: The delivery issue. Trends Neurosci., 24: 533-540, 2001.
57. Lohr, M., Hoffmeyer, A., Kroger, J., Freund, M., Hain, J., Holle, A., Karle, P., Knofel, W. T., Liebe, S., Muller, P., Nizze, H., Renner, M., Saller, R. M., Wagner, T., Hauenstein, K., Gunzburg, W. H., and Salmons, B. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357: 1591-1592, 2001.
58. Muller, P., Jesnowski, R., Karle, P., Renz, R., Saller, R., Stein, H., Puschel, K., von Rombs, K., Nizze, H., Liebe, S., Wagner, T., Gunzburg, W. H., Salmons, B., and Lohr, M. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors. Ann. N Y Acad. Sci., 880: 337-351, 1999.
59. Joza, N., Susin, S. A., Daugas, E., Stanford, W. L., Cho, S. K., Li, C. Y., Sasaki, T., Elia, A. J., Cheng, H. Y., Ravagnan, L., Ferri, K. F., Zamzami, N., Wakeham, A., Hakem, R., Yoshida, H., Kong, Y. Y., Mak, T. W., Zuniga-Pflucker, J. C., Kroemer, G., and Penninger, J. M. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature (Lond.), 410: 549-554, 2001.
60. Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., Larochette, N., Goodlett, D. R., Aebersold, R., Siderovski, D. P., Penninger, J. M., and Kroemer, G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature (Lond.), 397: 441-446, 1999.
61. Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, R. L., Simpson, R. J., and Vaux, D. L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell, 102: 43-53, 2000.
62. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 102: 33-42, 2000.
63. Hawkins, C. J., Silke, J., Verhagen, A. M., Foster, R., Ekert, P. G., and Ashley, D. M. Analysis of candidate antagonists of IAP-mediated caspase inhibition using yeast reconstituted with the mammalian Apaf-1-activated apoptosis mechanism. Apoptosis, 6: 331-338, 2001.
64. Aghi, M., Hochberg, F., and Breakefield, X. O. Prodrug activation enzymes in cancer gene therapy. J. Gene Med., 2: 148-164, 2000.